Kim Lab At Stanford University News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Biotechnology Company Centivax Officially Launches
News provided by
Share this article
Share this article
SAN FRANCISCO, April 29, 2021 /PRNewswire/  Centivax Inc. is proud to announce its launch on Jan. 1, 2021, as a fully independent biotechnology company developing broad-spectrum therapeutics and a vaccines portfolio, including indications in COVID-19, multi-drug resistant bacteria, influenza, antivenom and oncology. Our unusually mature portfolio of fully owned Centivax assets has been made possible by advanced computational immunoengineering technology platforms and intellectual property that enable Centivax to rapidly create the broad-spectrum antibodies and broad-spectrum vaccines clearly needed in 21st-century medicine, says Dr. Jacob Glanville, Founder and CEO of Centivax. It is these platforms that enable Centivax to enter clinical development of our first therapeutic within eight months of launch. ....

Nicholas Bayless , David Gangemi , Pamela Garzone , Jacob Glanville , Sawsan Youssef , David Tsao , Stephanie Wisner , Naval Medical Research Center , Walter Reed Army Institute Of Research , National Institute For Innovation , National Institute Of Health , Melinda Gates Foundation , Lab At University Of Kent , University Of San Francisco Biotechnology , Auburn University , Infectious Diseases Research Program , Kim Lab At Stanford University , Scripps Research Institute , Galveston National Labs , University Of Georgia , University Of San Carlos , Centivax Inc , Regulatory Affairs For Centivax , Technology Enterprise Consortium , Stanford University , Distributed Bio ,